Backgrounds/Aims: International treatment guidelines for branch duct intraductal papillary mucinous neoplasm (BD-IPMN) of the pancreas have been proposed, for features associated with malignancy and invasiveness. We investigated the clinicopathological characteristics that are predictive of malignancy or invasiveness and disease recurrence. Methods: A review of 324 patients with resected and pathologically confirmed BD-IPMN, between March 1997 and December 2013, was conducted. Results: There were 144 (44.4%) low grade dysplasia (LGD), 138 (42.6%) intermediate grade dysplasia (IMGD), 17 (5.3%) high grade dysplasia (HGD), and 25 (7.7%) invasive carcinoma (invIPMC) cases. The 5-year survival rates were 98.1% for LGD, 95.3% for IMGD, 100% for HGD, and 71.8% for invIPMC. Through a univariate analysis, the male sex was associated with malignancy, and CA19-9 was related to both malignant and invasive IPMN. The high risk or worrisome features of the international guidelines were associated with both malignant and invasive IPMN: the total bilirubin of the head/uncinate lesion, tumor size, mural nodule, and the size of the main pancreatic duct (MPD). Through a multivariate analysis, the male sex, elevated CA19-9, mural nodule, and dilated MPD diameter were independently correlated with the malignant IPMN. The elevated CA19-9 and dilated MPD diameter were also correlated with invasive carcinoma. The patient age and the initial pathological diagnosis were strongly associated with disease recurrence following surgical resection. Conclusions: The high risk or worrisome features in the current treatment guidelines for BD-IPMN are confined to the morphological characteristics of the disease. Patient factors and biological features should also be considered in order to develop optimal therapeutic or surveillance strategies. 
INTRODUCTION
Accompanying the development of novel diagnostic instruments, such as endoscopic ultrasonography or magnetic resonance imaging, asymptomatic cystic tumors of the pancreas have been identified and diagnosed with increasing frequency. 
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Classifying these morphological subtypes of ductal involvement is important for deciding upon a treatment strategy.
International consensus guidelines for the management of IPMN were established in 2006, and revised in 2012. 12, 13 In the 2012 guidelines, surgical resection for MD-IPMN was strongly recommended for all surgically fit patients, with the exception of cases having a main pancreatic duct (MPD) dilation of 5-9 mm; in this instance, the treatment strategies for BD-IPMN are more complicated, and it is these cases for which the concepts of 'high-risk stigmata of malignancy' and 'worrisome features' were adopted. 'High-risk stigmata of malignancy', in BD-IPMN, includes obstructive jaundice in a patient with a cystic lesion of the head of the pancreas, an enhancing solid component within the cyst, and an MPD size of ≥10 mm. 'Worrisome features' include a cyst size of ≥3 cm, thickened/enhancing cyst walls, an MPD size of 5-9 mm, a non-enhancing mural nodule, and an abrupt change in the caliber of the pancreatic duct with distal pancreatic atrophy. 13 In this study, we retrospectively reviewed the pathologically confirmed BD-IPMN in patients who underwent surgical resection. The clinicopathological characteristics of BD-IPMN were investigated, by associating the malignant and invasive tendencies with the levels of the total bilirubin, the MPD diameter, the tumor size, and the presence of mural nodules that were classified as 'high-risk stigmata' and/or 'worrisome features,' and we assessed the correlation of these parameters with patient survival and recurrence patterns. 
MATERIALS AND METHODS

Patient survival
Patient survival curves are shown in Fig. 1A and 1B.
The 5-year survival rates were 98.1% in LGD, 95.3% in IMGD, 100% in HGD, and 71.8% in invIPMC cases (Fig.   1A ). Although HGD was included in malignant IPMN, the three survival curves for LGD, IMGD, and HGD were not significantly different. We did detect a significant difference between noninvasive IPMN and invasive IPMC (p ＜0.001; Fig. 1B ).
Multivariate analysis of factors associated with malignant or invasive IPMN Among the factors associated with malignant IPMN described in Table 1 , we identified four statistically sig- Disease recurrence following surgical resection There were 16 patients who experienced disease recurrence following surgical resection; their clinicopathological characteristics are described in Table 3 Table 3 ). 2 of the initially noninvasive IPMN patients experienced carcinomatous recurrences (peritoneal seeding and liver metastasis) at 22.5 and 24.9 months following surgical resection, and died as a consequence of disease progression (No. 9 and 11; Table 3 ).
Old age, an elevated level of CA19-9 (＞37 U/ml), a dilated MPD diameter (≥10 mm), and invasive pathology were associated with disease recurrence via a univariate analysis (p=0.036, p＜0.001, p=0.006, and p＜0.001, respectively; Table 4 ). According to the multivariate analysis, old age (OR 1.092) and invasive IPMC (OR 32.840) patients were independently significant, in regard to disease recurrence following surgical resection.
DISCUSSION
IPMN is a disease entity that has a wide range of histological subtypes, and a natural history that follows an adenoma-to-carcinoma sequence. Knowledge of the natural history and disease traits of each subtype of IPMN is important for devising treatment strategies that avail patients of optimal treatment opportunities. International consensus guidelines for the management of IPMN were generated to assist in devising treatment strategies, by the working group of the International Association of Pancreatology.
The 2012 guidelines adopted new concepts, 'high-risk stigmata of malignancy' and 'worrisome features,' so we stratified patients into these two categories. 13 The recommendation of these guidelines was to let the stratified pa- The prevalence of malignant IPMN was reported to range from 10% to 32% in patients with BD-IPMN. 5, 10, 15, 16 In the series presented here, malignant IPMN (HGD and invIPMC) was 13.0%, and invasive carcinoma (invIPMC) was 7.7% of the entire resected BD-IPMN cohort.
Therefore, the proportion of malignant or invasive diseases of BD-IPMN would be reduced if non-resected noninvasive BD-IPMNs under observation had been included. Previously, patients with invasive IPMC were reported to be more likely to recur with a probability of hazard ratio of 5.2, but the original pathology did not predict disease severity on recurrence. 17 Here, we observed recur- Table 3 ). Those cases initially had a single lesion in the pancreas, and the resected margins were clear from disease. Therefore, there must still be undisclosed biological characteristics of IPMN, and molecular or large scale clinical studies to prevent the deaths of patients with initially benign disease should be considered.
In conclusion, in a high-volume single-institutional study, we investigated the clinicopathological characteristics of BD-IPMN of the pancreas. Although the current treatment guidelines for BD-IPMN reflect malignant and invasive features appropriately, they are confined to the morphological characteristics of the disease. Patient factors and biological features should be considered when devising optimal therapeutic or surveillance strategies.
